UNLIMITED TURBO LONG - IPSEN | Market Closed - Euronext Paris 17:30:00 31/05/2024 BST | ||
| 0.61 EUR | +11.93% |
|
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
IPSEN
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 0.61 | +11.93% |
| 30/05/24 | 0.545 | +1.87% |
| 29/05/24 | 0.535 | +5.94% |
| 28/05/24 | 0.505 | -17.21% |
| 27/05/24 | 0.61 | -14.08% |
Real-time Euronext Paris
Last update May 31, 2024 at 05:30 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | IPSEN |
| Issuer | 
BNP Paribas
|
| X6ZOB | |
| ISIN | FRBNPP06TVF3 |
| Date issued | 08/05/2024 |
| Strike | 110.1 € |
| Maturity | Unlimited |
| Parity | 20 : 1 |
| Emission price | 0.23 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.745 € |
|---|---|
| Lowest since issue | 0.31 € |
Company Profile
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows:
- oncology (75.2%);
- neuroscience (21.1%);
- rare diseases (3.7%).
At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide.
Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).
Sector
-
Consensus: Ipsen
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
120.6
EUR
Average target price
126.4
EUR
Spread / Average Target
+4.81%
- Stock Market
- Certificates
- X6ZOB Certificat